Systematic reviews and network meta-analysis are increasingly used to establish the comparative effectiveness of health technologies
Developing the statistical pooling of trial evidence, NMA is used to compare estimates of effectiveness across a range of treatments, and is most useful where direct randomized evidence between all relevant comparators is limited or unavailable.
ICON Commercialisation & Outcomes have considerable expertise in conducting NMA and have been involved in developing the methodology as well as contributing to the ISPOR best practice guidelines.
Network meta-analysis and systematic reviews are used to inform clinical decision-making and are recognized internationally as tools for treatment comparison. Their importance has been formally acknowledged by HTA bodies; including NICE (UK), CADTH (Canada) and PBAC (Australia) who have published technical reviews on these methodologies. Payers in the US and major European markets are becoming more interested in these analyses.
Our Health Economics and Epidemiology teams have extensive experience in conducting systematic reviews and meta-analysis, and have a wealth of expertise in the critical review of results of clinical trials and observational studies.
We have conducted reviews over a wide range of therapeutic areas. The team prides itself on constantly advancing knowledge and expertise and is active in the development of scientific methods.